Forestier et al. J Neurol. 2020


 

Cytotoxic lesion of the corpus callosum as presenting neuroradiological manifestation of COVID-2019 infection.  Forestier G, de Beaurepaire I, Bornet G, Boulouis G. J Neurol. 2020 Aug 18;. doi: 10.1007/s00415-020-10166-1. [Epub ahead of print] PubMed PMID: 32809155; PubMed Central PMCID: PMC7433278.

 

Since December 2019, severe acute respiratory syndrome (SARS) cases related to the coronavirus disease-2019 (COVID-19) emerged from Wuhan, Hubei Province, China [13] and spread all around the world contaminating more than 17 million people (> 174,000 cases in France) [4]. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) leads to a wide spectrum of mild disease most of the time with respiratory system being the most commonly affected organ. Still, coronaviruses have an established neuroinvasive propensity [5, 6], and MRI findings associated with acute neurological manifestations in COVID-19 patients have been recently reported [7, 8] to explain to some extent the neurological symptoms of patients infected with the SARS-CoV-2.

CLOCCs (previously termed Mild Encephalitis/Encephalopathy with Reversible Splenial lesion: MERS) is a rare infection-associated encephalopathy, involving cell-cytokine interactions [9], commonly described in the context of virus infections, metabolic disturbances, or antiepileptic drug. This syndrome presenting with great clinical heterogeneity [10], and complete regression of symptoms [11]. We hereby report the first case of cytotoxic lesion of the corpus callosum (CLOCCs) as presenting neuroradiological manifestation of COVID-2019 infection confirmed by chest computed tomography and nasopharyngeal swab sample test.